Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $32.4 million.

  • Catalyst Pharmaceuticals' Cash from Operations fell 5548.57% to $32.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $234.7 million, marking a year-over-year increase of 448.71%. This contributed to the annual value of $239.8 million for FY2024, which is 6699.72% up from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Cash from Operations is $32.4 million, which was down 5548.57% from $71.3 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Cash from Operations registered a high of $72.9 million during Q3 2024, and its lowest value of $3.8 million during Q1 2021.
  • For the 5-year period, Catalyst Pharmaceuticals' Cash from Operations averaged around $38.1 million, with its median value being $32.4 million (2025).
  • In the last 5 years, Catalyst Pharmaceuticals' Cash from Operations surged by 16449.88% in 2024 and then plummeted by 5548.57% in 2025.
  • Quarter analysis of 5 years shows Catalyst Pharmaceuticals' Cash from Operations stood at $19.2 million in 2021, then soared by 109.0% to $40.1 million in 2022, then skyrocketed by 38.85% to $55.6 million in 2023, then rose by 27.37% to $70.9 million in 2024, then tumbled by 54.23% to $32.4 million in 2025.
  • Its Cash from Operations stands at $32.4 million for Q3 2025, versus $71.3 million for Q2 2025 and $60.0 million for Q1 2025.